halometasone
Sign in to saveAlso known as SIE401
Halometasone is a potent (Group III) synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other regions such as China, Hong Kong, Turkey, Israel, South Africa and India.
Research
72 papers- Topical halometasone cream combined with fire needle pre-treatment for treatment of primary cutaneous amyloidosis: Two case reports.World journal of clinical cases · 2022
- Halometasone 0.05% cream in eczematous dermatoses.The Journal of clinical and aesthetic dermatology · 2013
- Effect of halometasone cream combined with Simiao pill on the therapeutic effect and expression of serum leukotriene B4 (LTB4) and thymic stromal lymphopoietin (TSLP) in patients with eczema, and the factors influencing its clinical efficacy.Annals of palliative medicine · 2021
- Halometasone monohydrate (0.05%) in occupational contact dermatitis.Indian journal of pharmacology · 2016
- Efficacy and Safety of Fractional CO(2) Laser Combined with Halometasone Cream for Treatment of Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial.Dermatology and therapy · 2023
via PubMed
Wikidata facts
- Mass
- 444.152
Show 4 more facts
- chemical formula
- C₂₂H₂₇ClF₂O₅
- isomeric SMILES
- C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C(=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)Cl)F
- canonical SMILES
- CC1CC2C3CC(C4=CC(=O)C(=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C)Cl)F
- World Health Organisation international non-proprietary name
- halometasone
via Wikidata · CC0
~1 min read
Article
1 sectionsContents
- References
Halometasone is a potent (Group III) synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other regions such as China, Hong Kong, Turkey, Israel, South Africa and India.
It has been used to treat chronic psoriasis vulgaris and non-infected acute eczematous dermatoses (eczema). One study demonstrated that 0.05% halometasone cream was more effective than 0.05% betamethasone cream in treating dermatitis, though both were well tolerated, with no systemic adverse effects reported.